drugset
drugset / Trial / NCT00724425

A Phase 1 Dose Escalation Study of IPI-493

NCT00724425 ↗

Phase 1 Terminated 53 enrolled Infinity Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.

Timeline

Start
2008-07
Primary completion
2011-07
Completion
2011-07

Outcome

Outcome not reported

Stopped: “Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus exclusively on retaspimycin”

Drugs

EvaluationDrugModalityDoseRoute
Subject IPI-493 Unknown — Oral

Indications

cancer